A claims-built read on the U.S. spinal cord stimulation market (CPT 63650 / 63655 / 63685 / 63688), drawn from all-payor claims on the Alpha Sophia platform. This brief shows the shape of the market — the full extract names every site.
The U.S. bills 460K+ SCS procedures a year across ~8,400 sites and 50+ states.
Volume is winner-take-most: the top 5% of sites drive about half of all trials; the top 10% drive roughly two-thirds.
The buying centers are office & ASC, not hospitals — clinics and surgery centers run nearly 90% of trial volume (hospitals just ~12%).
Generator implants are about 80% of permanent-implant volume — a recurring replacement & brand-switch pool.
The biggest opportunity is the trial-to-implant gap: high-volume sites that trial often but implant little.
Texas, Florida and California lead, on dense Sun Belt and upper-Midwest pain corridors.
Each tile is a state; darker tiles deliver more SCS trial procedures (CPT 63650). The pattern is what matters — a Sun Belt and Midwestern core with a long tail of emerging markets. Hover a state for an approximate read; site-level detail is in the full extract.
Source: Alpha Sophia all-payor claims intelligence · Stylized state-level view (teaser)
Ranked by CPT 63650 volume, rounded. Exact figures in the full extract.
What the map is telling us. SCS volume tracks the Sun Belt's older, faster-growing populations and the states with the most permissive ambulatory-surgery-center environments — Texas alone accounts for roughly one in eight U.S. trials, and the top six states drive over a third of national volume. The upper Midwest (Minnesota, Wisconsin, Ohio, Michigan) over-indexes too, reflecting dense independent pain and neurosurgery networks rather than population size.
The pale tiles matter just as much: the Northeast, Mountain West and Plains run cooler than their diagnosed-pain populations would predict — under-penetrated geographies where demand outstrips local implanting capacity. For a commercial team, the dark tiles are where to defend share and the pale ones are where to add it.
SCS is a two-step therapy: a percutaneous trial (CPT 63650) precedes a permanent implant. Across the market the step-down is steep — a huge, addressable pool of trials that never convert at the same site, whether lost to abandonment, attrition, or referral elsewhere.
See every high-trial, low-conversion site, ranked by implant gap — with names, NPIs and locations.
Billing data tells you who implants today. The real white space is the conversion gap — and the practices that see SCS-eligible pain patients but send the implant elsewhere. Alpha Sophia layers diagnosis and referral signals on top of SCS claims to surface latent demand, lapsed implanters and underpenetrated metros.
High-volume trial sites converting under half their trials to a permanent implant — support, training and displacement upside.
Sites running many trials and implanting few — patients leaving for someone else's OR. Prime capture & partner targets.
Markets with heavy chronic-pain and injection volume but few active implanters — where new capacity meets unmet demand.
SCS has moved decisively into office and physician-owned ambulatory settings. Hospitals bill barely one in eight trials, and the highest-throughput accounts are independent clinics and surgery centers — which reshapes how devices are sold, serviced and contracted.
Put together, clinics and physician-owned surgery centers run nearly 90% of U.S. SCS trial volume. For a device or service commercial team that means the decision-maker is usually an independent physician-owner or ASC administrator — not a hospital value-analysis committee.
Backed by the reporting. The migration of pain procedures and SCS into ambulatory surgery centers is well documented — see Becker's ASC on CMS site-of-service policy and ASC News on the NOPAIN Act's 2025 impact on ASC pain care, alongside CMS payment guidance.
Spinal cord stimulation is the anchor procedure of a broader shift in how America treats chronic pain: away from long-term opioids and toward durable, device-based, reimbursable therapy delivered in ambulatory settings. After years of steady-but-quiet growth, three forces have converged in the last 24 months to make this one of medtech's most actionable markets — and all of it is now visible, site by site, in claims.
At the same time, the locus of care has moved into physician-owned ambulatory surgery centers, and private equity has been actively consolidating interventional-pain practices — concentrating decision-making and raising the stakes on getting account targeting right. The result is a market that is simultaneously growing, fragmenting at the provider level, and consolidating at the ownership level. The pages that follow map exactly where the volume, the gaps, and the opportunity sit.
Spinal cord stimulation is an implantable neuromodulation therapy for chronic and treatment-refractory pain — a two-step trial-then-implant pathway, a multi-thousand-dollar device, and a battery that eventually needs replacing. It sits where three forces meet: a vast under-treated chronic-pain population, a non-opioid mandate, and a shift of cases into physician-owned ASCs.
The demand driver. Chronic pain affects tens of millions of U.S. adults, and the non-opioid imperative keeps pushing failed-back-surgery, CRPS and refractory-neuropathy patients toward neuromodulation as a guideline-supported next step.
The site-of-care driver. SCS economics increasingly favor physician-owned ambulatory surgery centers and office settings — where this data shows nearly 90% of trial volume now sits.
The technology driver. Closed-loop and high-frequency systems, rechargeable vs. non-rechargeable batteries, and MRI-conditional designs keep the field competitive — every end-of-battery generator swap is a moment a brand can be won or lost.
Device landscape: Boston Scientific, Medtronic, Abbott, Nevro and Saluda Medical compete on waveform, closed-loop sensing, battery and MRI compatibility. Clinical context via the North American Neuromodulation Society.
The recurring economics of SCS live in the pulse generator. Batteries deplete, technology advances, and patients return for a swap — each one a moment a competitor can win or lose the account. This is the single most commercially actionable signal in the dataset.
The replacement and revision pool is where brand-switching happens: an end-of-battery patient is the lowest-friction conversion target in neuromodulation. Tracking generator and revision volume by site reveals where an installed base is aging — and ripe to flip.
Beyond the state view, volume clusters in a set of ASC-heavy metros that punch well above their population — the right places to seed reference accounts and field coverage. Ranked by trial volume, rounded.
Volume concentrates fast at the top, but ownership stays remarkably dispersed below it. That gap — high site-level concentration, low corporate consolidation — is exactly the structure private equity and strategic acquirers look for.
For commercial teams, the read is twofold: concentrate field effort on the dense head, and watch the fragmented long tail as both a roll-up target list and a partner network. The implant-only sites are a referral map in disguise — the places trials flow to.
The biggest SCS trial & implant sites in the U.S. across CPT 63650, 63655 and 63685 — names anonymized. Org type and metro are shown; full identities, NPIs and exact volumes are in the report.
Names, NPIs, parent health systems, per-code volumes & conversion rates.
Sites trialing SCS at scale but converting a fraction into implants — the clearest targets for clinical support, capacity, or a competing device. Names anonymized; the full extract ranks every account by opportunity.
Every high-trial, low-conversion site — ranked by the implant gap, with names and locations.
This brief is a point-in-time read. The full report adds year-over-year SCS growth by state and by site — so you can see which markets are accelerating and where trial-to-implant conversion is climbing fastest.
Get the year-over-year trend report → 🔒 In full report
A transparent summary of the data, definitions and limitations behind the figures shown here.
Across all payors, more than 460,000 SCS procedures (CPT 63650, 63655, 63685 and 63688) are billed each year at roughly 8,400 sites across 50+ states, based on Alpha Sophia claims intelligence — about 270,000 trial/lead procedures and 165,000 permanent implants.
63650 is percutaneous implantation of an epidural neurostimulator electrode array (trials and permanent percutaneous leads). 63655 is a paddle lead placed via laminectomy. 63685 is insertion or replacement of the pulse generator — the marker of a permanent system and the recurring battery-replacement code. 63688 is revision or removal of the generator.
Texas, Florida, California, Arizona, Georgia and Tennessee lead on total volume, with dense Sun Belt and upper-Midwest concentration. Because one high-throughput ASC can dominate a metro, per-capita penetration often tells a more actionable story.
The spinal cord stimulation device market is estimated at roughly $3–4 billion in the mid-2020s and is widely forecast to grow at about 8% CAGR toward roughly $6–7 billion by the early 2030s, driven by chronic-pain demand and the non-opioid imperative.
The leading systems come from Boston Scientific, Medtronic, Abbott, Nevro and Saluda Medical, competing on waveform, closed-loop sensing, battery type and MRI compatibility.
The full Alpha Sophia extract names every billing site with NPIs, parent health systems, addresses, per-code mix, conversion rates and year-over-year trends. Request pricing.
This brief shows the shape of the market. The full Alpha Sophia extract gives you the site-by-site detail — and the demand-vs-supply layer — your commercial team needs to build territories and target the right accounts.
Book an extract scoping call →
Custom extracts available for any procedure, CPT/HCPCS set, specialty or geography. · Prefer email? isabel@alphasophia.com
This brief presents aggregated, approximate, state-level estimates derived from all-payor claims, for illustration. Figures are directional and rounded. CPT® is a registered trademark of the American Medical Association. Source: Alpha Sophia.